Sharat Singh

Statistics

Publications

Citations

5.8K

H-Index

Active since

1982

Affiliations

Prometheus Biosciences (United States)(Current)

Indian Institute of Science Bangalore

KU Leuven

Prometheus (United States)

University of Miami

Sharat Singh is an author at Prometheus Biosciences (United States) specializing in inflammatory bowel disease, gastrointestinal inflammation, and inflammation.

ORCID

Publications per year

1982–2022

Publications

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Violeta Serra, Maurizio Scaltriti, Ludmila Prudkin et al. · Oncogene · 2011 · 534 citations · Full text

Medicine, Cancer Biology, Pharmacology +17

An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer

Belén Rubio‐Viqueira, Antonio Jimeno, George Cusatis et al. · Clinical Cancer Research · 2006 · 412 citations · Full text

Medicine, Oncology, Pharmacology +16

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer

Moshe Elkabets, Sadhna Vora, Dejan Juric et al. · Science Translational Medicine · 2013 · 347 citations · Full text

Medicine, Oncology, Pharmacology +17

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

Niels Vande Casteele, Ann Gils, Sharat Singh et al. · The American Journal of Gastroenterology · 2013 · 344 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence.

Edwin F. Ullman, Hrair Kirakossian, Sharat Singh et al. · Proceedings of the National Academy of Sciences · 1994 · 336 citations

Natural Sciences, Biochemistry, Chemistry +17

1–5 of 56